CALM-AD

Summary

Primary Aim To determine whether; * Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment Secondary Aims To determine whether; * Donepezil has a significant positive or negative impact upon quality of life compared with placebo * whether there is a significant difference between Donepezil and placebo with respect to cognitive performance * the cost effectiveness of the pharmacological treatment for agitation

Timeline

Start

2003-11

Primary completion

—

Completion

2005-12

Publications

• Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007 Oct 4;357(14):1382-92. doi: 10.1056/NEJMoa066583.

Drugs

Indications